ZA200702976B - Polymorphic forms of 6-[2-(methylcarbamoyl)phenyl-sulfanyl]-3-E-[2-(pyrldin-2-yl)ethenyl]indazole - Google Patents
Polymorphic forms of 6-[2-(methylcarbamoyl)phenyl-sulfanyl]-3-E-[2-(pyrldin-2-yl)ethenyl]indazoleInfo
- Publication number
- ZA200702976B ZA200702976B ZA200702976A ZA200702976A ZA200702976B ZA 200702976 B ZA200702976 B ZA 200702976B ZA 200702976 A ZA200702976 A ZA 200702976A ZA 200702976 A ZA200702976 A ZA 200702976A ZA 200702976 B ZA200702976 B ZA 200702976B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrldin
- sulfanyl
- methylcarbamoyl
- indazole
- ethenyl
- Prior art date
Links
- WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 title 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62466504P | 2004-11-02 | 2004-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200702976B true ZA200702976B (en) | 2008-08-27 |
Family
ID=35538878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200702976A ZA200702976B (en) | 2004-11-02 | 2007-04-11 | Polymorphic forms of 6-[2-(methylcarbamoyl)phenyl-sulfanyl]-3-E-[2-(pyrldin-2-yl)ethenyl]indazole |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060094763A1 (enExample) |
| EP (1) | EP1819696A1 (enExample) |
| JP (1) | JP2008518904A (enExample) |
| KR (1) | KR20070060145A (enExample) |
| AR (1) | AR051945A1 (enExample) |
| AU (1) | AU2005300317A1 (enExample) |
| BR (1) | BRPI0517924A (enExample) |
| CA (1) | CA2586177A1 (enExample) |
| IL (1) | IL182580A0 (enExample) |
| MX (1) | MX2007005273A (enExample) |
| RU (1) | RU2007116150A (enExample) |
| TW (1) | TW200630356A (enExample) |
| WO (1) | WO2006048751A1 (enExample) |
| ZA (1) | ZA200702976B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2608952A1 (en) * | 2005-05-19 | 2006-11-23 | Dwayne Thomas Friesen | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| EP4249063A3 (en) * | 2007-04-05 | 2024-03-13 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| TW201328725A (zh) | 2011-09-30 | 2013-07-16 | Pfizer | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 |
| CA2855211A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CN104140414B (zh) * | 2013-05-07 | 2018-12-11 | 江苏豪森药业集团有限公司 | 阿昔替尼晶型的制备方法 |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| SI3102605T1 (sl) | 2014-02-04 | 2019-04-30 | Pfizer Inc. | Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka |
| CA2955676A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| WO2016178150A1 (en) * | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
| RU2766890C2 (ru) | 2015-06-16 | 2022-03-16 | Мерк Патент Гмбх | Комбинированные способы лечения антагонистами pd-l1 |
| WO2018065938A1 (en) | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| WO2020003196A1 (en) * | 2018-06-28 | 2020-01-02 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of axitinib |
| WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
| WO2020212253A1 (en) | 2019-04-18 | 2020-10-22 | Synthon B.V. | Process for preparing axitinib, process for purifying the intermediate 2-((3-iodo-1h-indazol-6-yl)thio)-n-methylbenzamide, process for purifying axitinib via the axitinib hcl salt, solid form of the axitinib hcl salt |
| WO2020225413A1 (en) | 2019-05-09 | 2020-11-12 | Synthon B.V. | Pharmaceutical composition comprising axitinib |
| PT3884929T (pt) | 2020-03-25 | 2023-08-09 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor da tirosina cinase |
| CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
| CN112174933A (zh) * | 2020-08-07 | 2021-01-05 | 天津理工大学 | 一种阿西替尼富马酸盐的新晶型及其制备方法 |
| CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
| CN114685437B (zh) * | 2020-12-25 | 2022-12-09 | 鲁南制药集团股份有限公司 | 阿昔替尼与糖精共晶 |
| CN114685431B (zh) * | 2020-12-26 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种阿昔替尼柠檬酸盐晶型 |
| CN114685433B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 一种阿昔替尼香草酸共晶盐及其制备 |
| CN114685435B (zh) * | 2020-12-28 | 2023-01-31 | 鲁南制药集团股份有限公司 | 阿昔替尼马来酸盐晶型及其制备 |
| CN114685432B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 阿昔替尼盐晶型及其制备方法 |
| CN114685438B (zh) * | 2020-12-28 | 2023-06-13 | 鲁南制药集团股份有限公司 | 一种阿昔替尼苹果酸新盐 |
| AU2023227442A1 (en) | 2022-03-03 | 2024-09-12 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
| AU2024251447A1 (en) | 2023-04-11 | 2025-08-21 | Ocular Therapeutix, Inc. | Ocular implant comprising axitinib polymorph iv |
| KR20250108329A (ko) | 2024-01-08 | 2025-07-15 | (주)유케이케미팜 | 엑시티닙의 제조방법 |
| WO2025157389A1 (en) | 2024-01-22 | 2025-07-31 | Iomx Therapeutics Ag | Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors |
| KR20250150872A (ko) * | 2024-04-12 | 2025-10-21 | 주식회사 스카이테라퓨틱스 | 액시티닙의 신규 분자 회합체 |
| KR102838026B1 (ko) * | 2024-04-30 | 2025-07-28 | 주식회사 스카이테라퓨틱스 | 액시티닙 신규 분자 회합체를 포함하는 점안 조성물 및 이의 제조방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
-
2005
- 2005-10-21 JP JP2007538541A patent/JP2008518904A/ja active Pending
- 2005-10-21 CA CA002586177A patent/CA2586177A1/en not_active Abandoned
- 2005-10-21 AU AU2005300317A patent/AU2005300317A1/en not_active Abandoned
- 2005-10-21 KR KR1020077010040A patent/KR20070060145A/ko not_active Ceased
- 2005-10-21 BR BRPI0517924-6A patent/BRPI0517924A/pt not_active IP Right Cessation
- 2005-10-21 RU RU2007116150/04A patent/RU2007116150A/ru not_active Application Discontinuation
- 2005-10-21 WO PCT/IB2005/003312 patent/WO2006048751A1/en not_active Ceased
- 2005-10-21 EP EP05796896A patent/EP1819696A1/en not_active Withdrawn
- 2005-10-21 MX MX2007005273A patent/MX2007005273A/es not_active Application Discontinuation
- 2005-10-31 US US11/264,493 patent/US20060094763A1/en not_active Abandoned
- 2005-11-01 TW TW094138274A patent/TW200630356A/zh unknown
- 2005-11-01 AR ARP050104569A patent/AR051945A1/es unknown
-
2007
- 2007-04-11 ZA ZA200702976A patent/ZA200702976B/xx unknown
- 2007-04-16 IL IL182580A patent/IL182580A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070060145A (ko) | 2007-06-12 |
| CA2586177A1 (en) | 2006-05-11 |
| IL182580A0 (en) | 2007-07-24 |
| AR051945A1 (es) | 2007-02-21 |
| TW200630356A (en) | 2006-09-01 |
| EP1819696A1 (en) | 2007-08-22 |
| JP2008518904A (ja) | 2008-06-05 |
| MX2007005273A (es) | 2007-07-19 |
| RU2007116150A (ru) | 2008-11-10 |
| AU2005300317A1 (en) | 2006-05-11 |
| US20060094763A1 (en) | 2006-05-04 |
| WO2006048751A1 (en) | 2006-05-11 |
| BRPI0517924A (pt) | 2008-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL182580A0 (en) | Polymorphic forms of 6-[2- | |
| IL197420A0 (en) | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1- | |
| IL196876A0 (en) | 2-(heterocyclylbenzyl)pyridazinone derivatives | |
| SG119330A1 (en) | Improved shirttails for reducing damaging effects of cuttings | |
| IL208963A0 (en) | Substituted quinoline compounds | |
| IL187845A0 (en) | Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl) | |
| IL193265A0 (en) | Quinoline derivatives | |
| ZA200703436B (en) | Methods for increasing maize yields | |
| EP1955697A4 (en) | 2-AMINOBENZAMIDE DERIVATIVE | |
| PL1912647T3 (pl) | Pochodne chinoliny jako środki antybakteryjne | |
| AU312580S (en) | Eyewear | |
| IL185129A0 (en) | Process for making montelukast and intermediates therefor | |
| AP2008004444A0 (en) | New anti-malaria derivatives of 4-aminoquinoline | |
| IL175696A0 (en) | Montelukast sodium polymorphs | |
| GB0504314D0 (en) | Novel polymorph | |
| PT1968944T (pt) | Alquilosulfonamida-quinolinas | |
| IL189857A0 (en) | Alkyl sulfoxide quinolines as nk-3 receptor ligands | |
| MA28510B1 (fr) | Sel de clopidogrel et formes polymorphes associees | |
| TWI340650B (en) | Amine saly of carbostyril derivative | |
| EP1878719A4 (en) | HYDROXYNOREPHEDRINE DERIVATIVE HYDROCHLORIDE POLYMORPH CRYSTAL | |
| ZA200802118B (en) | Alkyl sulfoxide quinolines as NK-3 receptor ligands | |
| IL195844A0 (en) | Polymorphic forms and process | |
| ZA200706872B (en) | Process for making montelukast and intermediates therefor | |
| GB2428638B (en) | Method of estimating alignment | |
| ZA200605575B (en) | Substituted quinoline compounds |